(Q37777006)

English

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

scientific article published on July 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1 reference

Europe PubMed Central

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

major depressive disorder

1 reference

based on heuristic

inferred from title

object named as

Leslie Citrome

1

0 references

language of work or name

0 references

publication date

1 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Postgraduate Medicine

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

122

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

39-48

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Therapeutic options for treatment-resistant depression

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Compelling or irrelevant? Using number needed to treat can help decide

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Individualizing treatment decisions. The likelihood of being helped or harmed

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Size of treatment effects and their importance to clinical research and practice

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Relative vs. absolute measures of benefit and risk: what's the difference?

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Evidence based medicine: what it is and what it isn't

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2174

21 January 2018

Identifiers

10.3810/PGM.2010.07.2174

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37777006&oldid=2109956905"